Key facts
- This page summarizes Charles K. Dargan's Form 4 filing for BIOLARGO, INC. (BLGO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Feb 2026, 14:56.
Charles K. Dargan - 01 Feb 2026 Form 4 Insider Report for BIOLARGO, INC. (BLGO)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- BLGO
- Reported as of
- 01 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Feb 2026, 14:56:55 UTC
- Prior SEC filing
- 03 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ John R. Browning, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Charles K. Dargan filed Form 4 for BIOLARGO, INC. (BLGO) on 03 Feb 2026.
Change
- Previous filing in this sequence was filed on 03 Feb 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001112799
Primary reporting owner
DARGAN CHARLES K
- Relationship
- Chief Financial Officer
- Address
- 18851 NE 29TH AVENUE, SUITE 700, AVENTURA
- Signature
- /s/ John R. Browning, attorney-in-fact
- Signature date
- 03 Feb 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BLGO
transaction
Derivative
Option to Purchase Common Stock
Award
- Transaction value
- Shares
- +300,000
- Change %
- +5.3%
- Price
- Shares after
- 5,931,668
- Date
- 01 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $0.1790
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from February 1, 2026, through January 31, 2027.